Celiac Disease - Pipeline Review, H2 2017 Market Report; Launched via MarketResearchReports.com

Celiac Disease - Pipeline Review, H2 2017, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.

Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren’s syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet.

Report Highlights

Celiac Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 10 and 6 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Celiac Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 83 pages “Celiac Disease - Pipeline Review, H2 2017” report covers Introduction, Report Coverage, Celiac Disease - Overview, Celiac Disease - Therapeutics Development, Celiac Disease - Therapeutics Assessment, Celiac Disease - Companies Involved in Therapeutics Development, Celiac Disease - Drug Profiles, Product Description, Celiac Disease - Dormant Projects, Appendix. This report Covered Companies - Amgen Inc, Calypso Biotech SA, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd, ImmusanT Inc, Innovate Biopharmaceuticals Inc, Intrexon Corp, Selecta Biosciences Inc, Takeda Pharmaceutical Company Ltd, Topas Therapeutics GmbH, Zedira GmbH.

Please visit this link for more details: http://mrr.cm/U3p

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Fibrosis - Pipeline Review, H2 2017 - Visit at - http://mrr.cm/U3G

Sinusitis - Pipeline Review, H2 2017 - Visit at - http://mrr.cm/U3N